Chief Executive Officer
Our Company
History
Eradivir’s founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.
Leadership
- Chief Operating Officer
- Chief Scientific Officer
- VP of Discovery
- VP of R&D
- Director of Drug Development
- Director of R&D
- Clinical Programs Director
Board of Directors
- Professor of Pediatrics
- Clinical Professor of Medicine
- CEO, Connor Group
- Chief Executive Officer
- Distinguished Professor of Chemistry
The Future of Medicine
Incredible things can happen when people come together with one shared goal. The future of medicine is happening here, and we're eager to work alongside inspired people who want to improve health around the world.